Lipid-lowering medications for children and adolescents

摘要: As demonstrated by the 2011 publication of National Heart, Lung, and Blood Institute Integrated Guidelines for Cardiovascular Health Risk Reduction in Children Adolescents, information available regarding treatment pediatric lipid disorders has greatly expanded. HMG-CoA reductase inhibitor, or statin, therapy is now considered a first-line pharmacologic intervention patients with severe dyslipidemias failing diet exercise alone. Despite their ability to effectively reduce cholesterol levels, bile acid sequestrants continue pose challenges because unpalatability are typically used as adjunctive not able tolerate statins. Fibric derivatives, class medications, only lack Food Drug Administration (FDA)-approved agent, but also significant safety efficacy data. Niacin, potential adjunct therapy, lacks FDA approval plagued adverse effects making it an unlikely option patients. Ezetimibe provides clinicians alternative when synergistically paired inhibitor can be monotherapy intolerant statins sequestrants. Finally, despite several marketed formulations, omega-3 fish oils currently have failed demonstrate statistically lowering adolescent Although recent years witnessed dramatic increase data use lipid-lowering medications patients, long-term study still generally lacking continues present active focus research.